Ellagic acid may be used as a promising pre-therapy to prevent the methotrexate-induced hepatotoxicity. - GreenMedInfo Summary
Ellagic acid as a potential antioxidant, alleviates methotrexate-induced hepatotoxicity in male rats.
Acta Chir Belg. 2018 Mar 28:1-9. Epub 2018 Mar 28. PMID: 29587597
Saeed Mehrzadi
BACKGROUND: Hepatotoxicity is one of the most life-threatening side-effects of Methotrexate therapy. Former studies highlighted the significance of oxidative stress in promoting Methotrexate-induced hepatotoxicity (MIH). Hence, the current study investigated the protective effect of Ellagic acid (EA), a poly-phenolic antioxidant, against MIH.
METHODS: Twenty-eight male Wistar rats were grouped into four sets: group 1 (control), group 2 (injected intraperitoneally with 20 mg/kg of Methotrexate on the 9th day), group 3 (treated orally with 10 mg/kg/day of EA for 10 days and injected with Methotrexate on the 9th day) and group 4 (treated with EA for 10 days). Subsequently, biochemical and histopathological parameters were evaluated in serum samples and liver tissues.
RESULTS: Methotrexate significantly increased activities of aminotransferases and ALP enzymes as well as levels of oxidative stress parameters in liver tissue. Likewise, Methotrexate decreased hepatic reduced glutathione level and activities of antioxidant enzymes. EA pre-treatment markedly attenuated the activities of aminotransferases and ALP, levels of oxidative stress parameters and augmented activities of antioxidant enzymes. Similarly, the remarkable protective effect of EA on liver has been confirmed by histological examination.
CONCLUSION: In sum, the current study supports the hypothesis that EA may be used as a promising pre-therapy to prevent the MIH.
